At the ADA annual conference, researchers reported the most current findings from two phase 3a clinical studies of oral Semaglutide. Researchers conducted these trials. In diabetes mellitus type 2 (T2DM) patients, this peptide has been shown to lower blood sugar levels and assist in weight loss. This is in comparison to the medicine that serves as the control. Semaglutide, an analog of natural human glucagon-like peptide-1 (GLP-1), can increase insulin production in a glucose-dependent manner, decrease hunger and food intake, and block glucagon release. In the past, it was tested in several clinical studies and succeeded each time.
Semaglutide has now been made available.
Semaglutide, an analog of natural human glucagon-like peptide-1 (GLP-1), can increase insulin production in a glucose-dependent manner, decrease hunger and food intake, and block glucagon release. In the past, it was tested in a series of clinical studies and had favorable results. Compared to Liraglutide, Semaglutide has a longer fat chain and a greater degree of hydrophobicity; nevertheless, Semaglutide is changed by short chain PEG, and as a result, its hydrophilicity is significantly improved. PEG modification cannot only tightly bind to albumin and hide the hydrolysis site of the DPP-4 enzyme but also decrease renal excretion, increase the biological half-life, and produce the effect of extended circulation.
The way it works
Semaglutide is a glucagon-like peptide-1 receptor agonist. It stimulates insulin production, a hormone that lowers sugar levels in the blood. Additionally, it seems to encourage the development of beta cells in the pancreas, the organ responsible for insulin production. On the other side, it inhibits glucagon production, leading to a rise in blood sugar. It does this by suppressing hunger and slowing digestion in the stomach, contributing to a lower overall food intake. In this manner, it contributes to the reduction of overall body fat.
Clinical trials
The clinical studies known as PIONEER 2 and PIONEER 4, respectively, were the source of the data that was made public. At the end of the first trial, the glycosylated hemoglobin (A1C) level was considerably lower than that of the control medication empagliflozin (25 mg) and oral Semaglutide (14 mg), with the results coming in at 0.9% and 1.3%, respectively (p 0.0001); researchers found this result in the first trial. In addition to this, the primary clinical end objective has been attained. Patients whose A1C levels were considerably reduced at the secondary clinical end goal after taking Semaglutide orally for 52 weeks also had these results. There were no discernible distinctions in the amount of weight reduction between the two.
In the 26th week of the PIONEER 4 clinical trial, oral Semaglutide (14 mg) demonstrated non-inferiority in A1C levels compared with Victoza. Victoza was the control medication in the study. Compared to the placebo, there was a considerable reduction in the A1C level. Compared to the effects of Victoza and the placebo after 52 weeks, experts showed the impact of A1C to be superior. At 26 and 52 weeks, Semaglutide, when taken orally, performed better than Victoza and the placebo in weight reduction. Researchers showed this impact to be statistically significant after 52 weeks. Specifically, those who used oral Semaglutide dropped 4.3 kilograms, whereas those who took Victoza and a placebo lost 3.0 kilograms and 1.0 kilograms, respectively.
The future
Although its safety and effectiveness have been demonstrated, GLP-1 receptor agonists have not been wholly employed in clinical practice. This is even though these agonists are both safe and effective. Patients with type 2 diabetes may benefit from taking Semaglutide orally since it has the potential to become the first oral GLP-1 receptor agonist. You can find this compound if you are a researcher, here.